BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지

Antitumor Responses of Adoptively-Transferred Tumor-Specific T-Cell Cultures in a Murine Lymphoma Model

  • Kim, Hee-Sue (College of Pharmacy, Chungnam National University) ;
  • Lee, Hee-Gu (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Lim, Jong-Seok (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Lee, Ki-Young (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Kim, Jae-Wha (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Chung, Kyeong-Soo (College of Pharmacy, Chungnam National University) ;
  • Choe, Yong-Kyung (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Choe, In-Seong (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Chung, Tai-Wha (Molecular and Cellular Biology Research Group, Korea Research Institute of Bioscience & Biotechnology) ;
  • Kim, Kil-Hyoun (College of Pharmacy, Ewha Womans University)
  • Received : 1995.11.20
  • Published : 1995.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of this study was to establish an in vitro culture method of tumor-specific T cells, and determine the efficacy of the cultured tumor-specific cytotoxic T-lymphocytes (CTL) as an agent of anti-tumor immunotherapy against a murine lymphoma, TIMI.4. Tumor-specific T-lymphocytes derived from C57BL/6 mice (thy-1.2) immune to TIMI.4 were activated by in vitro stimulation with the irradiated TIMI.4 cells, and expanded by restimulation with TIMI.4 in the presence of the concanavalin A-stimulated rat spleen culture supernatant, and splenic antigen-presenting cells. In vitro restimulation enhanced markedly the proportion of $CD8^+$, a predominant surface marker of CTL and the cytotoxic activity in the cultured immune T cell population. The resulting TIMI.4-specific T cells were adoptively transferred into nude mice. The tumor cells residing in the host after 7 days of adoptive transfer to B6.PL (thy-1.1) mice were quantified by use of an antibody directed to the thy-1.2 allele. The TIMI.4 cells in the recipient nude mice were decreased in a dose-dependent manner. Anti-tumor activity of the TIMI.4-specific T cells was also demonstrated by a survival test, where the tumor-bearing nu/nu mice which received the activated T-cells survived about 30% longer than the control mice which received the tumor cells alone. These suggest that adoptive transfer of TIMI.4-specific T cells could be a candidate for effective therapy of the murine lymphoma.

Keywords

References

  1. J. Immunol. v.134 Andrew, M.E.;Churilla, A.M.;Malck, T.R.;Braciale, V.L.;Braciale, T.J.
  2. J. Immunol. v.144 Brinchmann, J.E.;Gaudernack, G.;Vartdal, F.
  3. J. Immunol. v.17 Bruno, K.;Schild, H.;Hoegen, P.V.;Schirrmacher, V.
  4. J. Virol. v.51 Byme, J.A.;Oldstone, M.B.
  5. J. Exp. Med. v.167 Carbone, F.R.;Moore, M.W.;Scheiland, J.M.;Bevan, M.J. https://doi.org/10.1084/jem.167.6.1767
  6. J. Exp. Med. v.174 Jicha, D.L.;Rosenberg, S.A. https://doi.org/10.1084/jem.174.6.1511
  7. J. Immunol. v.64 Kannagi, M.;Masuda, T.;Hattori, T.
  8. J. Immunol. v.133 Kaplan, D.R.;Braciale, V.L.;Braciale, T.J.
  9. Cell v.59 Kast, W.M.;Offringa, R.;Peters, P.J. https://doi.org/10.1016/0092-8674(89)90006-8
  10. Int. J. Cancer v.6 no.SUP. Kast, W.M.;Melief, C.J.M.
  11. Cancer Res. v.50 Kern, D.E.;Klarnet, J.P.;Cheever, M.A.;Greenberg, P.D.
  12. Eur. J. Immunol. v.23 Koeppen, H.;Acena, M.;Drolet, A.;Rowley, D.A.;Schreiber, H. https://doi.org/10.1002/eji.1830231108
  13. Eur. J. Immunol. v.22 Kos, F.J. https://doi.org/10.1002/eji.1830221224
  14. J. Exp. Med. v.160 Lukacher, A.E.;Braciale, V.L.;Braciale, T.J. https://doi.org/10.1084/jem.160.3.814
  15. Advances in Cancer Research, Vol. 58 Melief, C.J.M.;Klein, G.(ed.);van De Woude, G.(ed.)
  16. Cancer Cells v.2 Melief, C.J.M.;Kast, W.M.
  17. Seminars in Cancer Biology v.2 Melief, C.J.M.;Kast, W.M.
  18. J. Virol. v.66 Moskophidis, D.;Pircher, H.
  19. Int. J. Cancer v.22 Moss, D.J.;Rickinson, A.B.;Pope, J.H. https://doi.org/10.1002/ijc.2910220604
  20. Cell Immunol. v.108 Naito, K.;Pellis, N.R.;Kahan, B.D. https://doi.org/10.1016/0008-8749(87)90230-9
  21. J. Immunol. v.149 Quentmeier, H.;Klaucke, J.;Drexler, H.G.
  22. Science v.234 Walker, C.M.;Moody, D.J.;Stites, D.P.;Levy, J.A. https://doi.org/10.1126/science.2431484
  23. J. Exp. Med. v.177 Welsh, R.M. https://doi.org/10.1084/jem.177.2.317
  24. Eur. J. Immunol. v.17 Cerundolo, V. https://doi.org/10.1002/eji.1830170204
  25. J. Immunol. v.125 Cheever, M.A.;Greenberg, P.D.;Fefer, A.
  26. J. Immunol. v.146 Crossland, K.D.;Lee, V.K.;Chen, W.;Riddell, S.R.;Greenberg, P.D.;Cheever, M.A.
  27. J. Immunol. v.132 Donahue, J.H.;Resenberg, M.;Chang, A.E.;Lotze, M.T.;Robb, R.J.;Rosenberg, S.A.
  28. J. Exp. Med. v.152 Fernandez-Cruz, E.;Woda, B.A.;Feldman, J.D. https://doi.org/10.1084/jem.152.4.823
  29. Progress in Experimental Tumor Research v.32 Greenberg, P.D.;Klarnet, J.P.;Kern, D.E.;Cheever, M.A.
  30. J. Immu. Methods v.135 Grooth, B.G.D.;Greve, J.;Garritsen, H.S.P.;Graft, M.V. https://doi.org/10.1016/0022-1759(90)90259-X
  31. Cancer Immunol. Immunother. v.28 Hoegen, P.V.;Schirrmacher, V. https://doi.org/10.1007/BF00205796
  32. Cell. Immunol. v.146 Huneycutt, B.S.;Cao, B.N.